

Amendments to the Specification:

Please amend the specification as follows:

Please replace the paragraph starting at page 17, line 31 with the following rewritten paragraph:

In the method of the invention the membrane assembly (1) is used in circumstances where it is necessary to terminate or reduce transdermal administration following topical application of the active in a transdermal formulation. The need to terminate or reduce transdermal administration may arise as a result of learning after the event that an overdose has been topically applied or the occurrence of adverse reaction or other any other factor which may lead to it being considered desirable to reduce the dose which would otherwise result from the initial topical application. The area of topical application (4) is identified and the membrane assembly applied preferably with sufficient dimensions to at least substantially cover the area of topical application (4). The membrane assembly (1) is applied to the skin in the area of application (4) so that the adhesive layer (6) on the skin contacting side (3) of the membrane ~~[[(3)]]~~ (2) makes adhering contact with the skin (4). Pressure, such as firm hand pressure, is preferably applied to the free surface (5) of the occlusive membrane (2) to urge the membrane assembly (1) into a uniformly adhering contact with the skin (4).

Please replace the paragraph starting at page 20, line 15 with the following rewritten paragraph:

The method of the invention may be used to reduce the level of administration of active agents from a range of transdermal formulations administered via patches, sprays or other topical methods. Such formulates will generally comprise an active agent, a carrier which preferably includes a volatile solvent and optionally a

penetration enhancer. The compositions will preferably contain a penetration enhancer. Examples of such compositions are disclosed in U.S. Pat. No. ~~6229900~~ 6,299,900, the contents of which are herein incorporated by reference. Examples of suitable carriers and penetration enhancers are described in U.S. Pat. No. ~~6,229,900~~ 6,299,900.